ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line

ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line

The combination of immune checkpoint inhibitors and anti-angiogenic therapy has become a first-line treatment option for advanced renal cell carcinoma (aRCC), with previous studies including patients of all IMDC risk levels. During a dedicated session on urological oncology at the 2023 ESMO Congress, Professor Sheng Xinan from Peking University Cancer Hospital, on behalf of a clinical research team, presented the results of the first Phase 3 study focusing on immune combination therapy for high-risk IMDC patients with advanced kidney cancer, making it the first domestic Phase 3 study of first-line immune combination therapy for advanced kidney cancer. The positive results offer a new first-line treatment option for patients with advanced kidney cancer.
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society for Medical Oncology (ESMO) 2023 Annual Congress, held in Madrid, Spain, on October 20, 2023, featured Professor Xiaojia Wang's poster presentation on the combination of anlotinib and fulvestrant (452P), providing new hope for these patients. Oncology Frontier invited Professor Xiaojia Wang from Zhejiang Cancer Hospital to share insights.
IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 congress in the United States, a predictive model for severe infection in infants under 90 days of age, based on clinical data and inflammatory biomarkers, was reported. This predictive model may aid in the early identification of newborns at high risk of severe infection, allowing timely clinical intervention to reduce the risk of disease progression. Dr. Mei Zeng from the Children's Hospital of Fudan University/National Children's Medical Center provides an introduction and commentary on this research.
IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

Precision treatment starts with accurate diagnosis. The clinical diagnosis of ventilator-associated pneumonia (VAP) is challenging, with a high misdiagnosis rate leading to excessive antibiotic use. At the recent 2023 IDWeek conference in the United States, a clinical trial was reported that utilized a bundled approach to VAP diagnosis and management. The results showed that it is safe and significantly reduces the respiratory culture positivity rate and antibiotic usage. Below, Professor Wang Yimin and his team from the China-Japan Friendship Hospital introduce and comment on this study.
Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

Carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have been designated as "urgent priorities" in antibiotic research and development by the WHO. Besides accelerating the development of new drugs, emphasizing the "repurposing" of existing drugs under antimicrobial stewardship (AMS) can help alleviate the threat of resistant bacteria. At the 2023 IDWeek congress, There is a study using oral fosfomycin as a step-down therapy for ESBL-E complicated urinary tract infections (cUTI), as an alternative to intravenous beta-lactam/beta-lactamase inhibitor (BL/BLIS) therapy, achieving non-inferiority results. Dr. Chun-hui Li from Xiangya Hospital, Central South University, introduces and comments on the study as follows.